2k8f › Citations

Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.

Feng H, Jenkins LM, Durell SR, Hayashi R, Mazur SJ, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, Bai Y
Structure 17 202-10 (2009)
Cited: 97 times
EuropePMC logo PMID: 19217391

Abstract

Coactivators CREB-binding protein and p300 play important roles in mediating the transcriptional activity of p53. Until now, however, no detailed structural information has been available on how any of the domains of p300 interact with p53. Here, we report the NMR structure of the complex of the Taz2 (C/H3) domain of p300 and the N-terminal transactivation domain of p53. In the complex, p53 forms a short alpha helix and interacts with the Taz2 domain through an extended surface. Mutational analyses demonstrate the importance of hydrophobic residues for complex stabilization. Additionally, they suggest that the increased affinity of Taz2 for p53(1-39) phosphorylated at Thr(18) is due in part to electrostatic interactions of the phosphate with neighboring arginine residues in Taz2. Thermodynamic experiments revealed the importance of hydrophobic interactions in the complex of Taz2 with p53 phosphorylated at Ser(15) and Thr(18).

Reviews - 2k8f mentioned but not cited (11)

  1. Protein lysine acetylation by p300/CBP. Dancy BM, Cole PA. Chem Rev 115 2419-2452 (2015)
  2. The tumor suppressor p53: from structures to drug discovery. Joerger AC, Fersht AR. Cold Spring Harb Perspect Biol 2 a000919 (2010)
  3. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Uversky VN, Davé V, Iakoucheva LM, Malaney P, Metallo SJ, Pathak RR, Joerger AC. Chem Rev 114 6844-6879 (2014)
  4. Role of Intrinsic Protein Disorder in the Function and Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and p300. Dyson HJ, Wright PE. J Biol Chem 291 6714-6722 (2016)
  5. p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept. Uversky VN. Int J Mol Sci 17 (2016)
  6. p53 N-terminal phosphorylation: a defining layer of complex regulation. Jenkins LM, Durell SR, Mazur SJ, Appella E. Carcinogenesis 33 1441-1449 (2012)
  7. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Curr Pharm Des 19 578-613 (2013)
  8. p53 Isoforms and Their Implications in Cancer. Vieler M, Sanyal S. Cancers (Basel) 10 (2018)
  9. Good Cop, Bad Cop: Defining the Roles of Δ40p53 in Cancer and Aging. Steffens Reinhardt L, Zhang X, Wawruszak A, Groen K, De Iuliis GN, Avery-Kiejda KA. Cancers (Basel) 12 E1659 (2020)
  10. Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy. Gao M, Zhou J, Su Z, Huang Y. Protein Sci 26 2334-2341 (2017)
  11. Studying the Structures of Relaxed and Fuzzy Interactions: The Diverse World of S100 Complexes. Ecsédi P, Gógl G, Nyitray L. Front Mol Biosci 8 749052 (2021)

Articles - 2k8f mentioned but not cited (24)

  1. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Feng H, Jenkins LM, Durell SR, Hayashi R, Mazur SJ, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, Bai Y. Structure 17 202-210 (2009)
  2. Electrostatically accelerated encounter and folding for facile recognition of intrinsically disordered proteins. Ganguly D, Zhang W, Chen J. PLoS Comput Biol 9 e1003363 (2013)
  3. Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein. Krois AS, Ferreon JC, Martinez-Yamout MA, Dyson HJ, Wright PE. Proc Natl Acad Sci U S A 113 E1853-62 (2016)
  4. Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex. Miller Jenkins LM, Feng H, Durell SR, Tagad HD, Mazur SJ, Tropea JE, Bai Y, Appella E. Biochemistry 54 2001-2010 (2015)
  5. Full-length p53 tetramer bound to DNA and its quaternary dynamics. Demir Ö, Ieong PU, Amaro RE. Oncogene 36 1451-1460 (2017)
  6. Anchoring intrinsically disordered proteins to multiple targets: lessons from N-terminus of the p53 protein. Huang Y, Liu Z. Int J Mol Sci 12 1410-1430 (2011)
  7. Highly precise protein-protein interaction prediction based on consensus between template-based and de novo docking methods. Ohue M, Matsuzaki Y, Shimoda T, Ishida T, Akiyama Y. BMC Proc 7 S6 (2013)
  8. Phosphorylation Regulates the Bound Structure of an Intrinsically Disordered Protein: The p53-TAZ2 Case. Ithuralde RE, Turjanski AG. PLoS One 11 e0144284 (2016)
  9. Structure of the Taz2 domain of p300: insights into ligand binding. Miller M, Dauter Z, Cherry S, Tropea JE, Wlodawer A. Acta Crystallogr D Biol Crystallogr 65 1301-1308 (2009)
  10. Modeling of RAS complexes supports roles in cancer for less studied partners. Engin HB, Carlin D, Pratt D, Carter H. BMC Biophys 10 5 (2017)
  11. Interaction of the transactivation domain of B-Myb with the TAZ2 domain of the coactivator p300: molecular features and properties of the complex. Oka O, Waters LC, Strong SL, Dosanjh NS, Veverka V, Muskett FW, Renshaw PS, Klempnauer KH, Carr MD. PLoS One 7 e52906 (2012)
  12. Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking. Jin, An X, Zhang Y, Zhao S, Duan L, Duan Y, Lian F, Tong X. Front Pharmacol 12 602218 (2021)
  13. Docking-based identification of small-molecule binding sites at protein-protein interfaces. Rosell M, Fernández-Recio J. Comput Struct Biotechnol J 18 3750-3761 (2020)
  14. Tumor-Suppressor p53TAD1-60 Forms a Fuzzy Complex with Metastasis-Associated S100A4: Structural Insights and Dynamics by an NMR/MD Approach. Dudás EF, Pálfy G, Menyhárd DK, Sebák F, Ecsédi P, Nyitray L, Bodor A. Chembiochem 21 3087-3095 (2020)
  15. Negatively charged, intrinsically disordered regions can accelerate target search by DNA-binding proteins. Wang X, Bigman LS, Greenblatt HM, Yu B, Levy Y, Iwahara J. Nucleic Acids Res 51 4701-4712 (2023)
  16. Network Pharmacology Combined with Bioinformatics to Investigate the Mechanisms and Molecular Targets of Astragalus Radix-Panax notoginseng Herb Pair on Treating Diabetic Nephropathy. Zhao J, Mo C, Shi W, Meng L, Ai J. Evid Based Complement Alternat Med 2021 9980981 (2021)
  17. Recognizing the Binding Pattern and Dissociation Pathways of the p300 Taz2-p53 TAD2 Complex. Li T, Motta S, Stevens AO, Song S, Hendrix E, Pandini A, He Y. JACS Au 2 1935-1945 (2022)
  18. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors. Kannan S, Partridge AW, Lane DP, Verma CS. Int J Mol Sci 20 (2019)
  19. Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage. Steffens Reinhardt L, Zhang X, Groen K, Morten BC, De Iuliis GN, Braithwaite AW, Bourdon JC, Avery-Kiejda KA. Cell Death Dis 13 907 (2022)
  20. Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathway. Ruan H, Yu C, Niu X, Zhang W, Liu H, Chen L, Xiong R, Sun Q, Jin C, Liu Y, Lai L. Chem Sci 12 3004-3016 (2020)
  21. Exploring the Antiovarian Cancer Mechanisms of Salvia Miltiorrhiza Bunge by Network Pharmacological Analysis and Molecular Docking. Xu X, Zhang Z, Liu L, Che C, Li W. Comput Math Methods Med 2022 7895246 (2022)
  22. Mechanistic insights into the renoprotective role of curcumin in cisplatin-induced acute kidney injury: network pharmacology analysis and experimental validation. Hui Z, Dong QQ, Shu HP, Tu YC, Liao QQ, Yao LJ. Bioengineered 12 11041-11056 (2021)
  23. Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme. Wu J, Li XY, Liang J, Fang DL, Yang ZJ, Wei J, Chen ZJ. Front Genet 13 940462 (2022)
  24. Other Subscriptions Nucleic Acids Res 42 iii-iii (2014)


Reviews citing this publication (14)

  1. Tumour suppression by p53: a role for the DNA damage response? Meek DW. Nat Rev Cancer 9 714-723 (2009)
  2. Posttranslational modification of p53: cooperative integrators of function. Meek DW, Anderson CW. Cold Spring Harb Perspect Biol 1 a000950 (2009)
  3. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Joerger AC, Fersht AR. Annu Rev Biochem 85 375-404 (2016)
  4. Transcriptional regulation in Saccharomyces cerevisiae: transcription factor regulation and function, mechanisms of initiation, and roles of activators and coactivators. Hahn S, Young ET. Genetics 189 705-736 (2011)
  5. Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Theillet FX, Binolfi A, Frembgen-Kesner T, Hingorani K, Sarkar M, Kyne C, Li C, Crowley PB, Gierasch L, Pielak GJ, Elcock AH, Gershenson A, Selenko P. Chem Rev 114 6661-6714 (2014)
  6. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Wang F, Marshall CB, Ikura M. Cell Mol Life Sci 70 3989-4008 (2013)
  7. Functional advantages of dynamic protein disorder. Berlow RB, Dyson HJ, Wright PE. FEBS Lett 589 2433-2440 (2015)
  8. Fine-tuning multiprotein complexes using small molecules. Thompson AD, Dugan A, Gestwicki JE, Mapp AK. ACS Chem Biol 7 1311-1320 (2012)
  9. The Transactivation Domains of the p53 Protein. Raj N, Attardi LD. Cold Spring Harb Perspect Med 7 (2017)
  10. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Hernández Borrero LJ, El-Deiry WS. Biochim Biophys Acta Rev Cancer 1876 188556 (2021)
  11. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Wang H, Guo M, Wei H, Chen Y. Signal Transduct Target Ther 8 92 (2023)
  12. Computational Methods to Predict Intrinsically Disordered Regions and Functional Regions in Them. Anbo H, Ota M, Fukuchi S. Methods Mol Biol 2627 231-245 (2023)
  13. Dynamic structures of intrinsically disordered proteins related to the general transcription factor TFIIH, nucleosomes, and histone chaperones. Okuda M, Tsunaka Y, Nishimura Y. Biophys Rev 14 1449-1472 (2022)
  14. Structural diversity of p63 and p73 isoforms. Osterburg C, Dötsch V. Cell Death Differ 29 921-937 (2022)

Articles citing this publication (48)

  1. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Loughery J, Cox M, Smith LM, Meek DW. Nucleic Acids Res 42 7666-7680 (2014)
  2. Expanding the proteome: disordered and alternatively folded proteins. Dyson HJ. Q Rev Biophys 44 467-518 (2011)
  3. The C terminus of p53 binds the N-terminal domain of MDM2. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A, Prives C. Nat Struct Mol Biol 17 982-989 (2010)
  4. The acidic transcription activator Gcn4 binds the mediator subunit Gal11/Med15 using a simple protein interface forming a fuzzy complex. Brzovic PS, Heikaus CC, Kisselev L, Vernon R, Herbig E, Pacheco D, Warfield L, Littlefield P, Baker D, Klevit RE, Hahn S. Mol Cell 44 942-953 (2011)
  5. Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Lee CW, Martinez-Yamout MA, Dyson HJ, Wright PE. Biochemistry 49 9964-9971 (2010)
  6. Quantitative analysis of multisite protein-ligand interactions by NMR: binding of intrinsically disordered p53 transactivation subdomains with the TAZ2 domain of CBP. Arai M, Ferreon JC, Wright PE. J Am Chem Soc 134 3792-3803 (2012)
  7. Mechanism of Mediator recruitment by tandem Gcn4 activation domains and three Gal11 activator-binding domains. Herbig E, Warfield L, Fish L, Fishburn J, Knutson BA, Moorefield B, Pacheco D, Hahn S. Mol Cell Biol 30 2376-2390 (2010)
  8. Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding. Andresen C, Helander S, Lemak A, Farès C, Csizmok V, Carlsson J, Penn LZ, Forman-Kay JD, Arrowsmith CH, Lundström P, Sunnerhagen M. Nucleic Acids Res 40 6353-6366 (2012)
  9. A sequence-specific transcription activator motif and powerful synthetic variants that bind Mediator using a fuzzy protein interface. Warfield L, Tuttle LM, Pacheco D, Klevit RE, Hahn S. Proc Natl Acad Sci U S A 111 E3506-13 (2014)
  10. Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. Nelson ML, Kang HS, Lee GM, Blaszczak AG, Lau DK, McIntosh LP, Graves BJ. Proc Natl Acad Sci U S A 107 10026-10031 (2010)
  11. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb. Jansma AL, Martinez-Yamout MA, Liao R, Sun P, Dyson HJ, Wright PE. J Mol Biol 426 4030-4048 (2014)
  12. Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly. He J, Ye J, Cai Y, Riquelme C, Liu JO, Liu X, Han A, Chen L. Nucleic Acids Res 39 4464-4474 (2011)
  13. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways. Ha JH, Shin JS, Yoon MK, Lee MS, He F, Bae KH, Yoon HS, Lee CK, Park SG, Muto Y, Chi SW. J Biol Chem 288 7387-7398 (2013)
  14. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain. D'Abramo M, Bešker N, Desideri A, Levine AJ, Melino G, Chillemi G. Oncogene 35 3272-3281 (2016)
  15. CCAAT/Enhancer-binding protein beta DNA binding is auto-inhibited by multiple elements that also mediate association with p300/CREB-binding protein (CBP). Lee S, Miller M, Shuman JD, Johnson PF. J Biol Chem 285 21399-21410 (2010)
  16. The 9aaTAD Transactivation Domains: From Gal4 to p53. Piskacek M, Havelka M, Rezacova M, Knight A. PLoS One 11 e0162842 (2016)
  17. Long-range modulation of chain motions within the intrinsically disordered transactivation domain of tumor suppressor p53. Lum JK, Neuweiler H, Fersht AR. J Am Chem Soc 134 1617-1622 (2012)
  18. Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain. Krois AS, Dyson HJ, Wright PE. Proc Natl Acad Sci U S A 115 E11302-E11310 (2018)
  19. Molecular dynamics of the full-length p53 monomer. Chillemi G, Davidovich P, D'Abramo M, Mametnabiev T, Garabadzhiu AV, Desideri A, Melino G. Cell Cycle 12 3098-3108 (2013)
  20. ETV4 and AP1 Transcription Factors Form Multivalent Interactions with three Sites on the MED25 Activator-Interacting Domain. Currie SL, Doane JJ, Evans KS, Bhachech N, Madison BJ, Lau DKW, McIntosh LP, Skalicky JJ, Clark KA, Graves BJ. J Mol Biol 429 2975-2995 (2017)
  21. Functional redundancy between the transcriptional activation domains of E2A is mediated by binding to the KIX domain of CBP/p300. Denis CM, Langelaan DN, Kirlin AC, Chitayat S, Munro K, Spencer HL, LeBrun DP, Smith SP. Nucleic Acids Res 42 7370-7382 (2014)
  22. On the intrinsic disorder status of the major players in programmed cell death pathways. Uversky AV, Xue B, Peng Z, Kurgan L, Uversky VN. F1000Res 2 190 (2013)
  23. Regulation of Androgen Receptor Activity by Transient Interactions of Its Transactivation Domain with General Transcription Regulators. De Mol E, Szulc E, Di Sanza C, Martínez-Cristóbal P, Bertoncini CW, Fenwick RB, Frigolé-Vivas M, Masín M, Hunter I, Buzón V, Brun-Heath I, García J, De Fabritiis G, Estébanez-Perpiñá E, McEwan IJ, Nebreda ÁR, Salvatella X. Structure 26 145-152.e3 (2018)
  24. Transcription Activation Domains of the Yeast Factors Met4 and Ino2: Tandem Activation Domains with Properties Similar to the Yeast Gcn4 Activator. Pacheco D, Warfield L, Brajcich M, Robbins H, Luo J, Ranish J, Hahn S. Mol Cell Biol 38 (2018)
  25. Real-time and simultaneous monitoring of the phosphorylation and enhanced interaction of p53 and XPC acidic domains with the TFIIH p62 subunit. Okuda M, Nishimura Y. Oncogenesis 4 e150 (2015)
  26. Bioinformatics study of cancer-related mutations within p53 phosphorylation site motifs. Ji X, Huang Q, Yu L, Nussinov R, Ma B. Int J Mol Sci 15 13275-13298 (2014)
  27. How p53 wields the scales of fate: arrest or death? Goh AM, Lane DP. Transcription 3 240-244 (2012)
  28. Characterization of the structural ensembles of p53 TAD2 by molecular dynamics simulations with different force fields. Ouyang Y, Zhao L, Zhang Z. Phys Chem Chem Phys 20 8676-8684 (2018)
  29. Dynamics of the Extended String-Like Interaction of TFIIE with the p62 Subunit of TFIIH. Okuda M, Higo J, Komatsu T, Konuma T, Sugase K, Nishimura Y. Biophys J 111 950-962 (2016)
  30. Phosphorylation of p53 Serine 15 Is a Predictor of Survival for Patients with Hepatocellular Carcinoma. Yang T, Choi Y, Joh JW, Cho SK, Kim DS, Park SG. Can J Gastroenterol Hepatol 2019 9015453 (2019)
  31. Structural features of human histone acetyltransferase p300 and its complex with p53. Banerjee S, Arif M, Rakshit T, Roy NS, Kundu TK, Roy S, Mukhopadhyay R. FEBS Lett 586 3793-3798 (2012)
  32. Binding Ensembles of p53-MDM2 Peptide Inhibitors by Combining Bayesian Inference and Atomistic Simulations. Lang L, Perez A. Molecules 26 (2021)
  33. Insight into a Transcriptional Adaptor Zinc Finger Encoded by a Putative Protein in the White Spot Syndrome Virus Genome. Shekar M, Venugopal MN. Interdiscip Sci 11 145-151 (2019)
  34. Structural Basis for the Interaction between p53 Transactivation Domain and the Mediator Subunit MED25. Lee MS, Lim K, Lee MK, Chi SW. Molecules 23 (2018)
  35. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX. Levy R, Gregory E, Borcherds W, Daughdrill G. Biomolecules 9 (2019)
  36. Crystal Structure of the CLOCK Transactivation Domain Exon19 in Complex with a Repressor. Hou Z, Su L, Pei J, Grishin NV, Zhang H. Structure 25 1187-1194.e3 (2017)
  37. DescribePROT: database of amino acid-level protein structure and function predictions. Zhao B, Katuwawala A, Oldfield CJ, Dunker AK, Faraggi E, Gsponer J, Kloczkowski A, Malhis N, Mirdita M, Obradovic Z, Söding J, Steinegger M, Zhou Y, Kurgan L. Nucleic Acids Res 49 D298-D308 (2021)
  38. Structural insights into TAZ2 domain-mediated CBP/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A. Lochhead MR, Brown AD, Kirlin AC, Chitayat S, Munro K, Findlay JE, Baillie GS, LeBrun DP, Langelaan DN, Smith SP. J Biol Chem 295 4303-4315 (2020)
  39. Characterization of the High-Affinity Fuzzy Complex between the Disordered Domain of the E7 Oncoprotein from High-Risk HPV and the TAZ2 Domain of CBP. Risør MW, Jansma AL, Medici N, Thomas B, Dyson HJ, Wright PE. Biochemistry 60 3887-3898 (2021)
  40. Comprehensive characterization of the embryonic factor LEUTX. Gawriyski L, Jouhilahti EM, Yoshihara M, Fei L, Weltner J, Airenne TT, Trokovic R, Bhagat S, Tervaniemi MH, Murakawa Y, Salokas K, Liu X, Miettinen S, Bürglin TR, Sahu B, Otonkoski T, Johnson MS, Katayama S, Varjosalo M, Kere J. iScience 26 106172 (2023)
  41. DescribePROT in 2023: more, higher-quality and experimental annotations and improved data download options. Basu S, Zhao B, Biró B, Faraggi E, Gsponer J, Hu G, Kloczkowski A, Malhis N, Mirdita M, Söding J, Steinegger M, Wang D, Wang K, Xu D, Zhang J, Kurgan L. Nucleic Acids Res 52 D426-D433 (2024)
  42. Epigenetic mechanisms to propagate histone acetylation by p300/CBP. Kikuchi M, Morita S, Wakamori M, Sato S, Uchikubo-Kamo T, Suzuki T, Dohmae N, Shirouzu M, Umehara T. Nat Commun 14 4103 (2023)
  43. How well does molecular simulation reproduce environment-specific conformations of the intrinsically disordered peptides PLP, TP2 and ONEG? Reid LM, Guzzetti I, Svensson T, Carlsson AC, Su W, Leek T, von Sydow L, Czechtizky W, Miljak M, Verma C, De Maria L, Essex JW. Chem Sci 13 1957-1971 (2022)
  44. Insights into a Cancer-Target Demethylase: Substrate Prediction through Systematic Specificity Analysis for KDM3A. Chopra A, Willmore WG, Biggar KK. Biomolecules 12 641 (2022)
  45. Most Probable Druggable Pockets in Mutant p53-Arg175His Clusters Extracted from Gaussian Accelerated Molecular Dynamics Simulations. Mustafa M, Gharaibeh M. Protein J 41 27-43 (2022)
  46. Semisynthetic 'designer' p53 sheds light on a phosphorylation-acetylation relay. Margiola S, Gerecht K, Müller MM. Chem Sci 12 8563-8570 (2021)
  47. Structural insights into p300 regulation and acetylation-dependent genome organisation. Ibrahim Z, Wang T, Destaing O, Salvi N, Hoghoughi N, Chabert C, Rusu A, Gao J, Feletto L, Reynoird N, Schalch T, Zhao Y, Blackledge M, Khochbin S, Panne D. Nat Commun 13 7759 (2022)
  48. VprBP/DCAF1 regulates p53 function and stability through site-specific phosphorylation. Ghate NB, Kim S, Mehmood R, Shin Y, Kim K, An W. Oncogene 42 1405-1416 (2023)


Quick links